Phase 2Completed
Efficacy of Intravenous Melatonin on Mortality in Adult Patients Admitted to the Intensive Care Unit With COVID-19 (MELCOVID)
A Phase II, Single-center, Double-blind, Randomized Placebo-controlled Trial to Explore the Efficacy and Safety of Intravenous Melatonin in Patients With COVID-19 Admitted to the Intensive Care Unit (MelCOVID Study)
- Sponsor
- Pharmamel S.L. (Industry)
- Enrolment
- 18 enrolled
- Conditions
- COVID-19; SARS-CoV 2; Coronavirus Infection
- Interventions
- Melatonin intravenous; Placebo intravenous
- Ages
- adults, older adults
- Registry
- NCT04568863
Full record on ClinicalTrials.gov
From the registry
There is an urgent need to evaluate effective treatments for COVID-19 patients. Melatonin has significant anti-inflammatory and antioxidant properties and it lacks of side-effects. This randomized controlled trial seeks to evaluate the efficacy of intravenous melatonin in reducing mortality in Covid-19 patients in the ICUs.
Primary outcomes
- Mortality
History
Last registry update
Primary completion
Registered
Started